BioMarin Pharmaceutical Inc.
BMRN
$66.16
$1.091.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.91% | 2.83% | 17.03% | 4.08% | 15.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.91% | 2.83% | 17.03% | 4.08% | 15.92% |
| Cost of Revenue | 27.83% | 20.47% | 12.68% | 47.19% | -0.91% |
| Gross Profit | 15.11% | -9.76% | 20.10% | -39.16% | 29.22% |
| SG&A Expenses | 32.91% | 21.28% | 21.59% | 5.89% | -11.69% |
| Depreciation & Amortization | 1,416.55% | -7.51% | -49.79% | -3.23% | -66.11% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.25% | 20.53% | 15.70% | 30.23% | -7.28% |
| Operating Income | -24.36% | -38.38% | 21.83% | -141.00% | 129.87% |
| Income Before Tax | -79.39% | -40.69% | -116.01% | -119.58% | 125.43% |
| Income Tax Expenses | -71.01% | -31.92% | -56.55% | -84.42% | 129.69% |
| Earnings from Continuing Operations | -81.39% | -43.17% | -137.28% | -128.98% | 124.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.39% | -43.17% | -137.28% | -128.98% | 124.43% |
| EBIT | -24.36% | -38.38% | 21.83% | -141.00% | 129.87% |
| EBITDA | 3.94% | -37.24% | 13.33% | -121.22% | 101.10% |
| EPS Basic | -81.54% | -43.62% | -136.98% | -128.74% | 122.35% |
| Normalized Basic EPS | -46.74% | -37.71% | 25.20% | -119.42% | 123.32% |
| EPS Diluted | -81.30% | -43.10% | -137.57% | -129.25% | 124.28% |
| Normalized Diluted EPS | -45.60% | -37.59% | 29.07% | -120.11% | 129.33% |
| Average Basic Shares Outstanding | 0.79% | 0.80% | 0.81% | 0.84% | 0.94% |
| Average Diluted Shares Outstanding | -1.33% | 0.61% | -2.22% | -2.59% | -1.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |